Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Yuan-Kai ShiKaijian LeiYuming JiaBingqiang NiZhiyong HeMinghong BiXicheng WangJianhua ShiMing ZhouQian SunGuolei WangDongji ChenYongqian ShuLianke LiuZhongliang GuoYong LiuJunquan YangKe WangKe XiaoLin WuTienan YiDebin SunMafei KangTianjiang MaYimin MaoJinsheng ShiTiegang TangYan WangPuyuan XingDongqing LvWangjun LiaoZhiguo LuoBin WangXiaohong WuXiaoli ZhuShuhua HanQisen GuoRongyu LiuZhiwei LuJianyong ZhangJian FangChanglu HuYinghua JiGuolong LiuHong LuDedong WuJunhong ZhangShuyang ZhuZheng LiuWensheng QiuFeng YeYan YuYanqiu ZhaoQinhong ZhengJun ChenZhanyu PanYiping ZhangWenjuan LianBo JiangBo QiuGuojun ZhangHua ZhangYanju ChenYuan ChenHongbing DuanManxiang LiShengming LiuLijun MaHongming PanXia YuanXueli YuanYulong ZhengEmei GaoLi ZhaoShumin WangCan WuPublished in: Cancer communications (London, England) (2021)
LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC. LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable, metastatic, or recurrent non-squamous NSCLC patients in the first-line setting.
Keyphrases
- phase iii
- small cell lung cancer
- double blind
- open label
- clinical trial
- placebo controlled
- high grade
- phase ii
- end stage renal disease
- low grade
- squamous cell carcinoma
- ejection fraction
- chronic kidney disease
- locally advanced
- phase ii study
- advanced non small cell lung cancer
- peritoneal dialysis
- newly diagnosed
- study protocol
- liver metastases
- metastatic colorectal cancer
- brain metastases
- radiation therapy
- combination therapy
- rectal cancer